Addressing the Leading Causes of Blindness
August 2023
DISCLAIMER
This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward- looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medical (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. It is also not intended to inform or guide clinical decisions.
nova-eye.com| 2
BUSINESS SNAPSHOT
Nova Eye Medical leads the way in interventional treatment solutions for glaucoma and age-related macular degeneration (AMD), the leading causes of blindness in the developed world.
Nova Eye Medical, Glaucoma
Strategy | Develop, market and sell comprehensive portfolio |
of glaucoma consumable surgical devices | |
Market | Canaloplasty segment of the glaucoma surgical |
devices market scheduled to grow rapidly 2022-27 | |
Sales | Established infrastructure; direct sales in USA, |
Germany, Australia; +20 distributors | |
Manufacturing | California, USA and Dunedin, New Zealand |
IP Status | >100 patents issued and pending |
Regulatory | Clearance in all key global markets, including USA |
(FDA) | |
Reimbursement | Favorable CPT codes (USA) |
AlphaRET, AMD
Strategy | Commercialise 2RT® to technology with |
partner | |
Intermediate Age-related Macular | |
Market | Degeneration treatment (iAMD) - market |
not addressed. Underserved market for | |
retinal disease therapy | |
Sales | Sales program to coincide with partnering |
Manufacturing | Adelaide, Australia based contract |
manufacturing | |
IP Status | First mover advantage, >10 patents issued |
and pending in major markets | |
CE Mark (iAMD and diabetic eye disease) | |
Regulatory | in Europe, Australia, NZ . FDA approval for |
diabetic eye disease | |
nova-eye.com| 3 |
COMPANY OVERVIEW
Capital Structure
ASX Code | EYE |
Share Price (at 28 July 2023) | $0.26 |
Shares on Issue | 190 M |
Share Price Chart
6,000,000 | $0.35 | |
Unlisted Options | 3.35 | M |
Market Capitalisation | $49.4 | M |
Cash | Capital raise | |
2 March 2023 | ||
~$7.5 M | ||
Shareholders |
Significant shareholder support from the top
20 shareholders
5,000,000
4,000,000
3,000,000
2,000,000
1,000,000
$0.30
$0.25
$0.20
$0.15
48%
52%
Top 20 Shareholders
0 | $0.10 | ||
1-Apr-202215-Apr-202229-Apr-202213-May-2022 | 27-May-202210-Jun-202224-Jun-20228-Jul-202222-Jul-20225-Aug-202219-Aug-20222-Sep-202216-Sep-202230-Sep-202214-Oct-202228-Oct-202211-Nov-202225-Nov-20229-Dec-202223-Dec-20226-Jan-202320-Jan-20233-Feb-202317-Feb-20233-Mar-202317-Mar-202331-Mar-202314-Apr-202328-Apr-202312-May-202326-May-20239-Jun-202323-Jun-20237-Jul-202321-Jul-2023 |
Volume | Share Price | nova-eye.com| 4 | |
OUR GLAUCOMA OPPORTUNITY
- With a proprietary product portfolio and an established glaucoma salesforce, Nova Eye Medical is well positioned to execute its glaucoma opportunity.
-
The new iTrack™ Advance canaloplasty device, cleared by the USA Food and Drug
Administration (FDA) in early
April 2023, offers significant opportunity for sales growth. - Capital raise of A$8 million in March 2023 successfully completed to support commercial roll-out of iTrack™ Advance.
Unique intellectual property drives product portfolio.
Paradigm shift towards earlier surgical intervention for glaucoma via MIGS driving an advanced global opportunity.
Already commercialised. Established glaucoma salesforce in the USA
nova-eye.com| 5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nova Eye Medical Ltd. published this content on 03 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2023 23:25:08 UTC.